Interim Results

Summary by AI BETAClose X

Bioventix plc reported unaudited interim results for the six months ended 31 December 2025, with revenue of £6.16 million, down from £6.73 million in the prior year, and profit before tax of £4.85 million, a decrease from £5.05 million. Despite this, closing cash balances increased to £5.3 million from £5.1 million, and the interim dividend remains at 70p per share. A significant highlight was the five-fold increase in Tau/neuro royalties to £150k, driven by the inclusion of Bioventix's monoclonal antibodies in research use only assays for Alzheimer's disease, with trading remaining in line with expectations for the full year.

Disclaimer*

Companies

Bioventix (BVXP)
UK 100

Latest directors dealings